From the Journals
From the Journals
COVID vaccination protects B cell–deficient patients through T-cell responses
The findings demonstrate how vaccine-induced T-cell responses could potentially reduce COVID-19 severity, the authors write.
Latest News
New consensus guide on rare drug hypersensitivity reaction
To support clinicians in diagnosing and managing DRESS, a steering committee conducted a literature review to examine current research, identify...
From the Journals
Low-dose methotrexate carries higher risk for older patients with CKD
Adverse event data showed an increased risk of myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects.
News
Chronic pain in the United States: New data
“This study identifies opportunities to improve guideline-concordant use of pharmacologic and nonpharmacologic therapies among adults with chronic...
Conference Coverage
Abatacept reduced rates of progression to RA, phase 2b trial finds
The study was conducted at 28 sites in the United Kingdom and 3 in The Netherlands.
Latest News
Do patients follow up on referrals after telehealth visits?
Investigators retrospectively examined test and referral orders for more than 4,000 patients to see how many complied with recommendations to have...
Opinion
Diagnosing patients with sarcoidosis
Sarcoidosis should always be part of the differential when you see lymphopenia.
From the Journals
Unexplained collapse unveils rare blood disorder
Acquired TTP often appears to arise in connection with either an immune trigger, such as a viral infection, or immune dysregulation associated...
From the Journals
Study eases fears: Knee surgery surge not linked to premature intervention
“The indications for surgery are not being eroded by operating on healthier patients to fill operating room time.”
From the Journals
Study confirms small blood cancer risk from CT scans
New research suggests that radiation exposure from CT scans heightens the risk of blood cancer in people under age 22.
Conference Coverage
Obinutuzumab promotes renal preservation in lupus nephritis
A post hoc analysis of the NOBILITY trial showed improved outcomes for patients taking obinutuzumab (Gazyva), compared with placebo.